Form 4: Olema Pharma Grants Executive 356,250 Stock Options

Olema Pharmaceuticals' Chief Discovery Officer, David C. Myles, was granted 356,250 stock options, including performance-based awards, effective February 2, 2026.

Summary

• David C. Myles, Chief Discovery & Non-Clinical Development Officer of Olema Pharmaceuticals, Inc. (OLMA), was granted a total of 356,250 derivative securities (stock options).
• This grant includes 250,000 stock options with a vesting schedule of 25% on February 2, 2027, and 1/48th of the total shares vesting monthly thereafter, contingent on continuous service.
• Additionally, 106,250 performance-based stock options were granted, eligible to vest based on the Issuer's stock price reaching pre-determined thresholds during two performance periods ending December 31, 2029, and December 31, 2030.
• All options have an exercise price of $25.65 and an expiration date of February 1, 2036.
• The transaction date for these grants was February 2, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting the company's commitment to retaining key talent and aligning executive incentives with long-term shareholder value through a standard equity compensation package.

Positives

• The grant of 356,250 stock options aligns the executive's interests with shareholder value creation, particularly through the performance-based options tied to stock price thresholds.
• The multi-year vesting schedule for the time-based options (25% on February 2, 2027, then monthly) promotes long-term retention of a key executive.
• The performance-based options incentivize the achievement of specific stock price targets, potentially driving strategic initiatives to boost market valuation.

Risks

• The value of the stock options is subject to the future performance of Olema Pharmaceuticals' stock price, which may not reach the exercise price or performance thresholds.
• The performance-based options carry the risk that the pre-determined stock price thresholds may not be achieved within the specified performance periods (ending December 31, 2029, and December 31, 2030).
• The vesting of both time-based and performance-based options is contingent on the Reporting Person's continuous service, posing a risk if employment ceases.

Future Outlook

The filing indicates a long-term commitment from a key executive, with equity incentives structured to vest over several years and tied to future stock price performance. This suggests an expectation of continued growth and value creation for Olema Pharmaceuticals, with specific stock price thresholds set for performance-based awards by December 31, 2029, and December 31, 2030.

Management Comments

• The performance-based stock options will be eligible to vest during two distinct performance periods... based on the Issuer's stock price trading at certain pre-determined price thresholds.
• Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date.

Industry Context

StockSavvy.ai notes that granting a mix of time-based and performance-based stock options is a common practice in the biotechnology and pharmaceutical industries. This compensation structure aims to retain key scientific and development talent while incentivizing them to achieve both long-term service and specific market-driven performance milestones, crucial for companies like Olema Pharmaceuticals focused on drug discovery and development.

Comparison to Industry Standards

• The grant of both time-based and performance-based options is consistent with executive compensation trends in the biotech sector, where aligning executive incentives with long-term shareholder value and specific operational or market milestones is standard.
• While specific comparable companies or projects are not detailed in the filing, similar equity incentive plans are observed at peer companies such as Moderna (MRNA) or BioNTech (BNTX), which frequently use stock options and restricted stock units with multi-year vesting and performance conditions to retain top scientific and executive talent.
• The exercise price of $25.65, being the market price at the time of grant, is a standard practice for incentive stock options, ensuring that the executive benefits only if the stock price appreciates.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for long-term value creation if the executive's incentives lead to improved company performance and stock price appreciation. Potential for minor dilution from option exercise in the future.
• Employees: May signal stability in executive leadership and a commitment to long-term strategic goals.
• Management: The executive receives significant equity incentives, aligning personal financial interests with the company's success.

Next Steps

• Continued service by David C. Myles to meet vesting conditions for both time-based and performance-based options.
• Olema Pharmaceuticals' stock price performance will be monitored against pre-determined thresholds for the performance-based options.
• Compensation Committee certification of achieved stock price thresholds for performance-based options.
• Vesting of 25% of time-based options on February 2, 2027, followed by monthly vesting thereafter.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (stock option grants) and does not contain information that would fundamentally alter the investment thesis for Olema Pharmaceuticals. While the grants align executive incentives with shareholder value, they are an expected part of compensation and do not provide new insights into the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Investors should continue to hold and monitor the company's core business developments and financial results.

Keywords

Olema Pharmaceuticals, OLMA, stock options, executive compensation, performance options, equity grant, insider transaction, David C. Myles, SEC Form 4, vesting, biotechnology, pharmaceuticals